Some prescribe GLP-1s to treat binge eating disorder a serious condition involving rapidly eating large meals with a loss of control, followed by feelings of intense shame despite these drugs not being approved for that purpose, says Elliott
So it's a way of gathering this data
Monami M, Cremasco F, Lamanna C, et al
Figure 3 shows that, while there were no or small differences in discontinuation rates between subgroups according to status of ASCVD, chronic kidney disease and heart failure among users of GLP-1 receptor agonists, discontinuation rates were higher among those with normal weight vs other weight categories
This is not a failure of science its how science works
Sources: CLC016634.A This content is not intended to be a substitute for professional medical advice, diagnosis or treatment